Antithrombotic Drug Therapy for IgA Nephropathy: A Meta Analysis of Randomized Controlled Trials

DOI Web Site 参考文献25件
  • Liu Xiu-Juan
    Division of Nephrology, 94 Hospital of Chinese PLA, PR China Division of Nephrology, Kidney Institute and Key Lab of Chinese People's Liberation Army (PLA), General Hospital of Chinese PLA, Postgraduate Medical College of Chinese PLA, PR China
  • Geng Yan-Qiu
    Division of Nephrology, Kidney Institute and Key Lab of Chinese People's Liberation Army (PLA), General Hospital of Chinese PLA, Postgraduate Medical College of Chinese PLA, PR China
  • Xin Shao-Nan
    Nanchang Military Academy of Chinese PLA, PR China
  • Huang Guo-Ming
    Division of Nephrology, 94 Hospital of Chinese PLA, PR China
  • Tu Xiao-Wen
    Division of Nephrology, 94 Hospital of Chinese PLA, PR China
  • Ding Zhong-Ru
    Division of Nephrology, 94 Hospital of Chinese PLA, PR China
  • Chen Xiang-Mei
    Division of Nephrology, Kidney Institute and Key Lab of Chinese People's Liberation Army (PLA), General Hospital of Chinese PLA, Postgraduate Medical College of Chinese PLA, PR China

書誌事項

公開日
2011
DOI
  • 10.2169/internalmedicine.50.5971
公開者
一般社団法人 日本内科学会

この論文をさがす

説明

Background Antithrombotic agents, including antiplatelet agents, anticoagulants and thrombolysis agents, have been widely used in the management of immunoglobulin A (IgA) nephropathy in Chinese and Japanese populations. To systematically evaluate the effects of antithrombotic agents for IgA nephropathy.<br> Methods Data sources consisted of MEDLINE, EMBASE, the Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Periodicals Databases (CNKI) and Japana Centra Revuo Medicina (http://www.jamas.gr.jp) up to April 5, 2011. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function.<br> Results Six articles met the predetermined inclusion criteria. Antithrombotic agents showed statistically significant effects on proteinuria (p<0.0001) but not on the protection of renal function (p=0.07). The pooled risk ratio for proteinuria was 0.53, [95% confidence intervals (CI): 0.41-0.68; I2=0%] and for renal function it was 0.42 (95% CI 0.17-1.06; I2=72%). Subgroup analysis showed that dipyridamole was beneficial for proteinuria (p=0.0003) but had no significant effects on protecting renal function. Urokinase had statistically significant effects both on the reduction of proteinuria (p=0.0005) and protecting renal function (p<0.00001) when compared with the control group.<br> Conclusion Antithrombotic agents had statistically significant effects on the reduction of proteinuria but not on the protection of renal function in patients with IgAN. Urokinase had statistically significant effects both on the reduction of proteinuria and on protecting renal function. Urokinase was shown to be a promising medication and should be investigated further.<br>

収録刊行物

  • Internal Medicine

    Internal Medicine 50 (21), 2503-2510, 2011

    一般社団法人 日本内科学会

参考文献 (25)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ